Cover Image
Market Research Report
Product code 
1056970

Hypoparathyroidism - Pipeline Insight, 2022

Published: Pre-Order | DelveInsight Business Research LLP | 60 Pages | Delivery time: 2-10 business days

Price

Back to Top
Hypoparathyroidism - Pipeline Insight, 2022
Published: Pre-Order
DelveInsight Business Research LLP
Content info: 60 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

DelveInsight's, "Hypoparathyroidism - Pipeline Insight, 2022," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Hypoparathyroidism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

  • Global coverage

Hypoparathyroidism Understanding

Hypoparathyroidism: Overview

Hypoparathyroidism is a rare condition in which the parathyroid glands fail to produce sufficient amounts of parathyroid hormone or the parathyroid hormone produced lacks biologic activity. The symptoms of hypoparathyroidism occur due to low levels of calcium in the blood. The severity of the condition can range from mild symptoms such as a tingling or numbness in the fingers, toes or around the lips (paresthesias) to severe muscle cramps and muscle spasms. The muscle symptoms are often called tetany, a condition characterized by uncontrollable twitching and cramping spasms of certain muscles such as those of the hands, feet, legs, and arms. In rare cases, seizures or fits can occur, or the level of consciousness can be depressed.

"Hypoparathyroidism - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypoparathyroidism pipeline landscape is provided which includes the disease overview and Hypoparathyroidism treatment guidelines. The assessment part of the report embraces, in depth Hypoparathyroidism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypoparathyroidism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

  • The companies and academics are working to assess challenges and seek opportunities that could influence Hypoparathyroidism R&D. The therapies under development are focused on novel approaches to treat/improve Hypoparathyroidism.

Hypoparathyroidism Emerging Drugs Chapters

This segment of the Hypoparathyroidism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hypoparathyroidism Emerging Drugs

  • TransCon PTH: Ascendis Pharma

TransCon™ PTH is an investigational prodrug of parathyroid hormone (PTH) in development as a once-daily hormone replacement therapy. It is designed to restore physiologic levels of PTH 24 hours a day. By doing so, we believe TransCon PTH can address both the short-term symptoms and long-term complications of hypoparathyroidism. The goal is to provide a PTH replacement therapy that normalizes serum and urinary calcium, as well as serum phosphate levels, and improves quality of life. TransCon PTH has orphan designation for the treatment of hypoparathyroidism in both the U.S. and Europe. The company has completed enrollment in the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism, with topline results expected in Q1 2022.

  • Encaleret: Calcilytix Therapeutics

Encaleret is an investigational small molecule antagonist of the calcium sensing receptor (CaSR). The CaSR is a G-protein-coupled receptor for which extracellular calcium is the primary ligand. The major physiologic role of the CaSR is to function conceptually as a 'calciostat' and maintain serum calcium levels by regulating the release of PTH and calcium reabsorption.

Further product details are provided in the report……..

Hypoparathyroidism: Therapeutic Assessment

This segment of the report provides insights about the different Hypoparathyroidism drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Hypoparathyroidism

There are approx. 8+ key companies which are developing the therapies for Hypoparathyroidism. The companies which have their Hypoparathyroidism drug candidates in the most advanced stage, i.e. phase III include, Ascendis Pharma.

  • Phases

DelveInsight's report covers around 8+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Hypoparathyroidism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hypoparathyroidism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypoparathyroidism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypoparathyroidism drugs.

Hypoparathyroidism Report Insights

  • Hypoparathyroidism Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Hypoparathyroidism Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Hypoparathyroidism drugs?
  • How many Hypoparathyroidism drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypoparathyroidism?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypoparathyroidism therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Hypoparathyroidism and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Ascendis Pharma
  • Calcilytix Therapeutics
  • Amolyt Pharma
  • AEterna Zentaris Inc
  • Chugai Pharmaceutical
  • Entera Bio
  • Sigilon Therapeutics
  • ProLynx
  • Extend Biosciences

Key Products

  • TransCon PTH
  • Encaleret
  • AZP 3601
  • PCO 371
  • EB612
  • EXT607
  • PTH(1-34)
  • AEZS 150
Product Code: DIPI0671

Table of Contents

Introduction

Executive Summary

Hypoparathyroidism: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Hypoparathyroidism - DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

  • Comparative Analysis

TransCon PTH: Ascendis Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Encaleret: Calcilytix Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

AZP 3601: Amolyt Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

PTH(1-34): ProLynx

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Hypoparathyroidism Key Companies

Hypoparathyroidism Key Products

Hypoparathyroidism- Unmet Needs

Hypoparathyroidism- Market Drivers and Barriers

Hypoparathyroidism- Future Perspectives and Conclusion

Hypoparathyroidism Analyst Views

Hypoparathyroidism Key Companies

Appendix

List of Tables

  • Table 1 Total Products for Hypoparathyroidism
  • Table 2 Late Stage Products
  • Table 3 Mid Stage Products
  • Table 4 Early Stage Products
  • Table 5 Pre-clinical & Discovery Stage Products
  • Table 6 Assessment by Product Type
  • Table 7 Assessment by Stage and Product Type
  • Table 8 Assessment by Route of Administration
  • Table 9 Assessment by Stage and Route of Administration
  • Table 10 Assessment by Molecule Type
  • Table 11 Assessment by Stage and Molecule Type
  • Table 12 Inactive Products

List of Figures

  • Figure 1 Total Products for Hypoparathyroidism
  • Figure 2 Late Stage Products
  • Figure 3 Mid Stage Products
  • Figure 4 Early Stage Products
  • Figure 5 Preclinical and Discovery Stage Products
  • Figure 6 Assessment by Product Type
  • Figure 7 Assessment by Stage and Product Type
  • Figure 8 Assessment by Route of Administration
  • Figure 9 Assessment by Stage and Route of Administration
  • Figure 10 Assessment by Molecule Type
  • Figure 11 Assessment by Stage and Molecule Type
  • Figure 12 Inactive Products